- Central Florida Division External Communications
At AdventHealth, two such treatments are now being deployed to treat the most seriously ill COVID patients: remdesivir and sarilumab. To receive these medications, patients must be in the intensive care unit and receiving oxygen support.
Given the urgency of the COVID-19 outbreak, the FDA is allowing hospitals to deploy the drugs outside of their officially approved uses. Remdesivir was originally developed to treat the Ebola virus; sarilumab is a treatment for moderate to severe rheumatoid arthritis.
Remdesivir is an antiviral drug that is designed to inhibit virus reproduction. Physicians are seeking to learn if remdesivir’s effects will extend to coronavirus patients too.
AdventHealth, along with leading medical institutions across the country, is administering sarilumab as part of a clinical trial to determine its effectiveness against COVID-19. Its normal function is to reduce inflammation in joints, so the hope is it will have a similar benefit in reducing the inflammatory response in the lungs of severely ill COVID patients.
“It’s very exciting that we are able to offer this trial to patients and determine what the best treatment is going to be for others with this condition,” said Dr. Amay Parikh, site principal investigator for the trial and medical director of the Neuro ICU at AdventHealth Orlando. “Having patients participate is going to help a lot more people across the nation.”
More than 30 patients have been enrolled in the sarilumab trial to date, and more are being sought nationwide.
The remdesivir and sarilumab treatments are part of a broad effort to bring innovative solutions to the fight against COVID-19. AdventHealth has launched a program to collect plasma of patients who’ve recovered from the disease to help those still struggling with the disease.
Recent News
AdventHealth President and CEO Terry Shaw has been named one of Modern Healthcare’s 100 Most Influential People in Healthcare for 2024, marking continued recognition of Shaw as a transformative leader...
AdventHealth has named Elise MacCarroll-Wright as president and CEO of UChicago Medicine AdventHealth Hinsdale in its Great Lakes Region, effective Jan. 6, 2025.
AdventHealth has named Dave Tkachuck president/CEO for UChicago Medicine AdventHealth La Grange, effective Jan. 6.
A UChicago Medicine AdventHealth neurologist addresses the growing gap between the number of men and women diagnosed with MS.
AdventHealth has named Ryan Quattlebaum president/CEO for AdventHealth Wesley Chapel, effective Dec. 29.
Health care and government leaders celebrate the much-anticipated expansion of AdventHealth University.
Wangsness has more than 30 years of experience in health care.
‘Imagine Wholeness’ features the Grammy-winning group Take 6 and the AdventHealth Orchestra.
Bejarano will assume leadership on Dec. 15, 2024.
The 25th anniversary of ‘To Err is Human’ provides an opportunity to reflect on key learnings that have shaped the hospital system’s culture of safety.
The agreement includes ShorePoint Health Port Charlotte, Certain Assets of ShorePoint Health Punta Gorda and a free-standing Emergency Department.
AdventHealth has achieved the top spot on the Gartner Healthcare Supply Chain Top 25 for 2024.